Treatment of ocular rosacea

Wladis, Edward J.; Adam, Alejandro P.

doi:10.1016/j.survophthal.2017.07.005

Cited by 34 publications

(41 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients should also be aware of the systemic associations with rosacea so that monitoring can be undertaken where appropriate. Exposure to potential triggers should be minimized, such as recommending the use of sun protection to minimize UV exposure, and minimizing hot showers, spicy foods, alcohol and caffeine 79 . Conservative measures to treat MGD are encouraged, including digital massage or the use of warm compresses and lid hygiene, twice daily, to treat posterior and anterior blepharitis 2 .…”

Section: Treatment Of Ocular Rosaceamentioning

confidence: 99%

Ocular manifestations of rosacea: A clinical review

Tavassoli

Wong

Chan

2021

Clinical Exper Ophthalmology

View full text Add to dashboard Cite

Ocular rosacea is a chronic inflammatory condition that can occur in the absence of cutaneous features. The most common ocular features are chronic blepharoconjunctivitis with eyelid margin inflammation and meibomian gland dysfunction. Corneal complications include corneal vascularization, ulceration, scarring and, rarely, perforation. Diagnosis is largely based on clinical signs, although it is often delayed in the absence of cutaneous changes, particularly in children. It can also be associated with systemic disorders such as cardiovascular disease. Management ranges from local therapy to systemic treatment, depending on the severity of the disease. In this review, we describe the epidemiology, pathophysiology, clinical features and treatment of rosacea and ocular rosacea.

show abstract

Section: Treatment Of Ocular Rosaceamentioning

confidence: 99%

Ocular manifestations of rosacea: A clinical review

Tavassoli

Wong

Chan

2021

Clinical Exper Ophthalmology

View full text Add to dashboard Cite

show abstract

“…Approximately 58%-72% of patients with rosacea develop ophthalmic findings. 28 Ocular rosacea results from meibomian gland dysfunction. This results in tearing, photophobia, and blurry vision.…”

Section: The Role Of Il-17 In the Pathophysiology Of Rosaceamentioning

confidence: 99%

“…Punctual occlusion can be used for refractory eye disease. 28 Cyclosporine is more effective in the treatment of ocular rosacea than doxycycline. Cyclosporine inhibits a variety of T-cell activities, including suppression of Th17 cells and subsequently inhibiting the production of IL-17.…”

Section: Challenges In the Treatment Of Rosaceamentioning

confidence: 99%

“…In its most severe form, ocular rosacea can result in erosions, ulceration, and corneal perforation. 28 An analysis of tear cytokines showed that D. folliculorum blepharitis patients ( n = 15) had significantly higher levels of tear cytokines; particularly IL-17 (95.1 ± 36.8 pg/mL) compared with D. folliculorum free blepharitis patients ( n = 15; 84.9 ± 21.6 pg/mL) and a normal control group with no ocular symptoms ( n = 15; 79.7 ± 21.0) demonstrated that D. folliculorum blepharitis patients had significantly higher levels of tear cytokines; particularly IL-17 compared to each control group ( P < .05), which resulted in inflammation of the lid margin and ocular surface. 29…”

Section: The Role Of Il-17 In the Pathophysiology Of Rosaceamentioning

confidence: 99%

See 1 more Smart Citation

The Role of IL-17 in Papulopustular Rosacea and Future Directions

Ali

Vender

2019

J Cutan Med Surg

View full text Add to dashboard Cite

Rosacea is a chronic, progressive, inflammatory condition phenotypically subtyped into diagnostic features, major features, and minor/secondary features. There is currently no cure for rosacea, and it carries a significant negative psychosocial burden for afflicted patients. While there are a number of treatment modalities at the disposal of the clinician, clinical experience has suggested a need for updated treatments. The pathogenesis of rosacea is multifactorial; however, this paper will focus on the pivotal role of interleukin 17 (IL-17) in the development and progression of the disease. Furthermore, this paper will explore the mechanism of action of standard rosacea treatments and their effect on different stages of the IL-17 pathway. The standard treatments for rosacea are usually effective in controlling the symptoms of the disease in its mild-to-moderate form; however, their efficacy is diminished in the setting of severe and treatment-resistant rosacea. We hypothesize that IL-17 inhibitors, currently used successfully in psoriasis and psoriatic arthritis, could perhaps be used to treat severe and treatment-resistant papulopustular rosacea in the future; however, clinical trials and case reports will be needed to dictate expanded indications of IL-17 inhibitors. Furthermore, the high cost of IL-17 inhibitors presently prevents their use in disease states other than psoriasis or psoriatic arthritis.

show abstract

“…PhR can be treated with CO 2 laser and sharp blade excision (5). The treatments of OR include pharmaceutical agents, laser and light based therapies, and surgical interventions (6).…”

Section: Introductionmentioning

confidence: 99%

Retrospective analysis of 19 papulopustular rosacea cases treated with oral minocycline and supramolecular salicylic acid 30% chemical peels

Wang

Wen

et al. 2020

Exp Ther Med

View full text Add to dashboard Cite

Papulopustular rosacea (PPR) is characterized by central facial erythema and transient papules and/or pustules, with or without telangiectases. The treatment of PPR is challenging due to the unclear and complex pathogenesis. In the present retrospective study, patients with PPR treated with oral minocycline and supramolecular salicylic acid (SSA) 30% chemical peels enrolled between June 2018 and June 2019 were evaluated. All patients were treated with 50 mg minocycline twice a day and SSA 30% twice a month. A total of 19 patients were enrolled and all received the therapy for 12 weeks. A significant reduction of rosacea severity was observed by Investigator Severity Assessment (ISA) after treatment; the mean score reduced from 3.32±0.6 at baseline to 0.89±0.7 (P<0.01) at 12 weeks. After 12 weeks, all patients achieved at least a 'moderate response' and 17 patients (89.47%) obtained 'excellent improvement' in the Investigator Global Assessment of efficacy. No obvious adverse reactions were observed during each patient's visit. In conclusion, the combination treatment of minocycline and SSA 30% was an effective therapy for PPR. The limitation of the present study was that it was a retrospective analysis; more high-quality, prospective, blinded, controlled clinical trials are required to evaluate the efficacy based on the current study.

show abstract

Treatment of ocular rosacea

Cited by 34 publications

References 68 publications

Ocular manifestations of rosacea: A clinical review

Ocular manifestations of rosacea: A clinical review

The Role of IL-17 in Papulopustular Rosacea and Future Directions

Retrospective analysis of 19 papulopustular rosacea cases treated with oral minocycline and supramolecular salicylic acid 30% chemical peels

Contact Info

Product

Resources

About